| 荣荣,陈小静,郭俊,李桂芳,孙明裕,赵家鑫,张世阳.沙库巴曲缬沙坦的研究进展[J].中国临床保健杂志,2020,23(5):713-716. |
| 沙库巴曲缬沙坦的研究进展 |
| Research progress of sacubitril/valsartan |
| 投稿时间：2019-09-01 |
| DOI：10.3969/J.issn.1672-6790.2020.05.034 |
| 中文关键词: 心力衰竭 沙库巴曲缬沙坦 依那普利 综述 |
| 英文关键词: Heart failure Sacubitril/valsartan Enalapril Review 〖FL |
| 基金项目:安徽省公益性联动项目(1604f0804009) |
|
| 摘要点击次数: 4468 |
| 全文下载次数: 5401 |
| 中文摘要: |
| 慢性心力衰竭的药物治疗已转变为神经内分泌抑制剂的修复性治疗策略,PARADIGM-HF研究结果显示,血管紧张素脑啡肽酶抑制剂沙库巴曲缬沙坦与依那普利相比可以进一步降低心血管死亡风险或心力衰竭住院风险。本文进一步回顾了沙库巴曲缬沙坦的有效性、安全性、耐受性以及它对血压控制的益处。最近开展的研究结果期待能在更广泛的心力衰竭人群中得到使用。 |
| 英文摘要: |
| Drug therapy for chronic heart failure has been transformed into a restorative strategy of neuro-endocrine inhibitors.The PARADIGM HF study showed that sacubitril/valsartan,an angiotensin receptor-neprilysin inhibitor (ARNi),further reduced the risk of cardiovascular death or hospitalization for heart failure compared with enalapril.This paper further reviewed the effectiveness,tolerance,and safety of sacubitril/valsartan.Also we described its additional effect of lowering blood pressure.The results of recent studies are excepted to be applied in a wider range of people with heart failure. |
|
查看全文
|
| 关闭 |
|
|
|